Cephalosporin Market by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Type (Branded and Generics), Route of Drug Administration (Injection and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection): Global Opportunity Analysis and Industry Forecast, 2018 - 2025
Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics that is majorly used to treat bacterial infections. It resembles penicillin and hence, is used as an alternative for patients who are allergic to penicillin. It is used in the treatment of a variety of clinical conditions, including pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, and gonorrhea.
The major factors that contribute to the growth of the cephalosporin market include increase in R&D activities to develop highly efficient & safe drugs, upsurge in use of combination therapies, and rise in prevalence of pneumonia, tonsillitis, bronchitis, and gonorrhea. Moreover, increased approvals of drugs and growth in awareness about various infections & antibiotic resistance propel the market growth. However, side effects associated with cephalosporin and development of drug-resistant bacterial strains impede the market growth. Conversely, increase in mergers and acquisition among key vendors and development of combination therapies in the untapped market are anticipated to provide potential opportunities for the market growth.
The global cephalosporin market is segmented on the basis of generation, type, route of drug administration, application, and region. Based on generation, the market is divided into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. By type, it is bifurcated into branded and generics. Depending on route of drug administration, it is classified into injection and oral. The applications covered in the study include respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS - The report provides an in-depth analysis of market trends, macro-economic indicators, and governing factors.
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the market through 2017–2025 that helps identify the upcoming market opportunities.
- Recent industry trends and developments and the future opportunities are also covered.
- Extensive knowledge about the key market players and their strategies is provided.
- Comprehensive analysis of the various factors that drive and restrain the growth of the market is provided.
Key Market Segments • By Generation
o First-generation Cephalosporin
o Second-generation Cephalosporin
o Third-generation Cephalosporin
o Fourth-generation Cephalosporin
o Fifth-generation Cephalosporin
• By Type
• By Route of Drug Administration
• By Application
o Respiratory Tract Infection
o Skin Infection
o Ear Infection
o Urinary Tract Infection
o Sexually Transmitted Infection
• By Region
o North America
- Rest of Europe
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key market players The key players operating in this market include
• Allergan Plc
• Bristol-Myers Squibb Company
• Lupin Limited
• Novartis International AG
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
Our reports have been used by over 10K customers, including:
125 pages •
By Global Industry Analysts
• Apr 2021
- Global Clostridium Difficile Treatment Market to Reach $1.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Clostridium Difficile Treatment estimated at US$878.9 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2027, growing at a CAGR of 5.1% over the...
Community Acquired Pneumonia (Infectious Disease) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Drugs in Development, 2021, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
Candidiasis Therapeutics Market Report Overview Candidiasis Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Candidiasis Therapeutics market types and applications. It is a focused study on Candidiasis Therapeutics market...
Cryptococcosis Therapeutics Market Report Overview Cryptococcosis Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Cryptococcosis Therapeutics market types and applications. It is a focused study on Cryptococcosis Therapeutics...
253 pages •
By Roots Analysis Private Ltd.
• Jan 2021
INTRODUCTION Medical researchers first began evaluating mRNA as a therapeutic modality in the 1990s. The clinical use of mRNA is presently being evaluated in both therapeutic (protein replacement therapies, and as an alternative to classical gene therapies) and preventive (mRNA vaccines) roles. There are over 65 mRNA therapeutics...
Plasma Protein Therapeutics Market Report Overview Plasma Protein Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Plasma Protein Therapeutics market types and applications. It is a focused study on Plasma Protein Therapeutics...
“Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complicated skin and soft tissue infections (cSSTI) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the...
“MIJ 821 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Treatment Resistant Depression in 7 Major Markets. A detailed picture of the MIJ 821 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.